Research methods
Why placebo controls are tricky in psychedelic trials
2026-10-16 · 3 min read
A participant in a psychedelic trial may be told that they could receive the study drug or a control. The treatment assignment can be carefully concealed, yet the experience may still give them a strong idea of which group they are in. The people supervising the session may form a guess too.
That problem matters when reading a study’s results. Expectations can influence how people describe their symptoms and how others assess them. Researchers have to consider both the treatment comparison and how well the assignment stayed hidden.
Randomization and blinding do different jobs
Randomization assigns participants to study groups by chance. Blinding, also called masking, keeps treatment assignments hidden from specified people. A trial may blind participants, clinicians, outcome assessors or several of these groups. The NCI explains randomization and double-blind studies in its research dictionary.
When reading a paper, look for the actual roles involved. Someone who supervises a session and someone who later scores symptoms can have different access to information.
When the experience gives the assignment away
Researchers call it functional unblinding when effects or behaviour allow people to infer the assigned treatment. In psychedelic studies, changes in perception can make this particularly difficult. Someone who notices those changes may expect improvement; someone who believes they received the control may expect less benefit.
The FDA’s July 2026 final guidance discusses this challenge. It considers alternatives to an inert placebo and recommends approaches such as central raters who are blinded to assignment and visit number. It also discusses questionnaires about treatment guesses and expectations.
Why an active placebo is used
An active placebo produces some noticeable effect, giving researchers a way to make the control experience less obviously different. The particular comparison still needs explaining in the study report.
In a 2023 randomized trial of psilocybin for major depressive disorder, researchers used niacin as an active placebo because it can cause flushing. Both groups received psychological support. Depression ratings were conducted by remote central raters who were blinded to treatment assignment, study visit and protocol details, helping separate outcome assessment from what happened in the session.
Those choices show why the control drug and the assessment process belong in the same discussion. Each addresses a different way knowledge or expectations could influence the comparison.
What to look for in the report
Start with the control group: what did participants receive, and what support did each group get? Then find who assessed the outcomes and what information they had. Check whether the researchers asked participants and staff to guess assignments, and whether those findings are reported.
Read the outcome definition and follow-up period alongside these details. Our guide to primary and secondary outcomes explains that part of a trial record.
The aim is to understand what was compared and how the result was measured. That gives you a more useful reading of a psychedelic trial than the label “double-blind” can provide on its own.